Our Take
This is a regulatory milestone, not a technical one—the sensor itself is unchanged; what shifted is who can legally buy it without a prescription.
Why it matters
Parents managing Type 1 diabetes in young children have relied on prescription CGMs or fingerstick testing. OTC clearance for ages 2+ removes the gatekeeping step and creates a direct-to-consumer market segment that didn't exist before.
Do this week
Pediatric diabetes program managers: audit your current glucose monitoring protocols this week to understand which families may now self-select Stelo outside the clinic workflow and plan for gaps in clinical oversight.
FDA clears Dexcom Stelo for children ages 2 and older
Dexcom announced that the Stelo over-the-counter glucose monitor has received FDA clearance for use in children as young as two years old. This is the first OTC continuous glucose monitoring system approved for pediatric use in this age group. The Stelo sensor itself is not new; Dexcom received OTC clearance for adults in 2023. The expansion to younger children represents the regulatory pathway broadening, not a product redesign.
The real story is distribution, not innovation
Until now, young children with Type 1 diabetes have required a prescription to access continuous glucose monitoring. Dexcom's OTC clearance removes that friction. A parent can now purchase Stelo directly without clinic involvement, then train themselves on the system independently.
This matters because it decouples glucose monitoring from clinical gatekeeping. Families with resources and motivation can begin CGM use earlier, outside the standard pediatric diabetes clinic workflow. The downside is equally obvious: children on Stelo without clinical oversight may miss interpretation errors or fail to escalate concerning patterns to their endocrinologist. OTC does not mean unsupervised; it means the supervision burden shifts from the clinic to the parent.
The market impact is secondary but real. Dexcom gains access to a segment previously locked behind prescription requirements. Parents gain choice. Pediatric diabetes programs lose visibility into early CGM adoption rates and may face new questions about when and how to integrate patient-purchased sensors into their care protocols.
Prepare for fragmented monitoring infrastructure
Clinical teams managing pediatric diabetes should expect that some patients will arrive at visits already using Stelo purchased OTC, without formal integration into the EHR or care plan. Programs should clarify their policy now: will they accept OTC Stelo data into the medical record? Will they require a prescription-based system if the child is also enrolled in the clinic? Will they educate families on the limitations of unsupervised CGM use?
The regulatory approval is straightforward. The operational question—how to fold OTC devices into a clinical workflow designed around prescribed systems—is not.